HeartSciences (HSCS) Notes Payables (2022 - 2026)

HeartSciences (HSCS) has reported Notes Payables for 5 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• Quarterly Notes Payables rose 41.98% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $3.6 million (up 41.98% YoY) and the FY2026 annual result came in at $3.6 million, up 41.98% from the prior year.
• Notes Payables climbed to $3.6 million in Q2 2026 per HSCS's latest filing, from $2.6 million in the prior quarter.
• Over the last five years, Notes Payables for HSCS reached as high as $3.6 million in Q2 2026 and fell as low as $130000.0 in Q3 2022.
• A 5-year average of $1.4 million and a median of $1.3 million in 2022 frame the typical range for Notes Payables.
• The largest YoY upside for Notes Payables was 410.23% in 2025 against a maximum downside of 78.87% in 2025.
• Year by year, Notes Payables stood at $1.1 million in 2022, then advanced by 25.41% to $1.4 million in 2023, then surged by 67.01% to $2.4 million in 2024, then rose by 7.79% to $2.6 million in 2025, then jumped by 41.98% to $3.6 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $3.6 million, $2.6 million, and $500000.0 for Q2 2026, Q4 2025, and Q4 2025 respectively.